Bispecific Antibodies Market Size, Share, Trends, Growth 2032

Bispecific Antibodies Industry Prospective:

The global bispecific antibodies market size was worth around USD 2.36 billion in 2023 and is predicted to grow to around USD 8.30 billion by 2032 with a compound annual growth rate (CAGR) of roughly 15.00% between 2024 and 2032.

Request Free Sample

Bispecific Antibodies Market: Overview

Bispecific antibodies (BsAbs) are next-generation medicines with vast applications in the treatment of serious diseases such as autoimmune disorders and cancer. BsAbs consist of two separate domains capable of binding to two epitopes of the same antigen or two antigens.

In the last decade, the BsAbs industry has witnessed several advancements due to the adoption of genetic engineering that facilitates the development of novel molecules with specific advantages and disadvantages. According to market research, bispecific antibodies are considered as next-generation monoclonal antibodies (mAbs). According to researchers, typical mAbs are useful in targeting only one antigen.

However, bispecific antibodies are equipped with joined mAbs and hence can target two antigens simultaneously. Thus, they are widely regarded in the treatment of multiple anti-tumor or physiological responses. Currently, the demand for BsAbs is growing due to the extensive application of medical treatment in cancer-related cases along with autoimmune, chronic inflammatory, and neurodegenerative diseases.

During the forecast period, the industry players can expect more revenue due to the growing demand for targeted cancer treatment. However, the high cost of research and medical treatment may limit the industry’s expansion rate along with regulatory challenges.

Key Insights:

• As per the analysis shared by our research analyst, the global bispecific antibodies market is estimated to grow annually at a CAGR of around 15.00% over the forecast period (2024-2032)
• In terms of revenue, the global bispecific antibodies market size was valued at around USD 2.36 billion in 2023 and is projected to reach USD 8.30 billion, by 2032.
• The market is projected to grow at a significant rate due to the growing prevalence of cancer and the demand for targeted therapy.
• Based on the indication, the cancer segment is anticipated to command the largest market share.
• Based on the distribution channels, the hospital pharmacies segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on region, North America is projected to dominate the global market during the forecast period.

Bispecific Antibodies Market: Growth Drivers

Growing prevalence of cancer and demand for targeted therapy will drive the market demand rate

The global bispecific antibodies market is projected to grow due to the growing prevalence of cancer across the globe. In addition to this, medical professionals are increasingly inclining toward targeted therapy further fueling the demand for BsAbs. According to market analysis, bispecific antibodies provide a sophisticated and novel approach to anti-cancer treatments. They assist in targeting different antigens in the body using the same range of action or mechanisms.

In addition to this, bispecific antibodies can be manipulated to generate multiple formats which, by extension, optimize molecular function for specific clinical contexts. BsAbs facilitate the introduction of immune cells directly to cancer-causing cells thus increasing the chances of the immune cells to target the cells causing the disease. Cancer is one of the world’s most prevalent diseases according to official reports.

Some of the most common forms of cancer include lung, breast, prostate, and stomach cancer. The disease is caused by uncontrolled growth of body cells. According to the World Health Organization (WHO, cancer is the second leading cause of death. The disease can severely impact the lives of the patients and their families, especially in countries with higher numbers of low and middle-income groups. Furthermore, the growing demand for effective cancer cures has pushed the use of bispecific antibodies, especially in the backdrop of the growing adoption of targeted anti-cancer therapies.

Rising cases of autoimmune disorders among the population will further create demand for BsAbs

Bispecific antibodies are also used for the treatment of several types of autoimmune diseases. BsAbs are used for managing and reducing inflammation that is often associated with autoimmune disorders driven by diverse cytokines and their receptors on immune cells. The most common autoimmune disorders include type 1 diabetes, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD), and others. The mounting pressure on the healthcare infrastructure to develop effective treatments for autoimmune conditions will fuel the demand in the global bispecific antibodies market.

Bispecific Antibodies Market: Restraints

High cost of engineering and regulatory challenges limits the overall revenue in the industry

The global industry for bispecific antibodies is projected to be restricted due to the high cost of engineering the next-generation treatment. The manufacturing design for BsAbs is highly complex requiring specialized equipment and skill sets. The process of BsAbs sanitization entails the use of cutting-edge molecular engineering procedures which directly impacts the cost of the research & development in the industry. Furthermore, the BsAbs sector is further impacted by the regulatory challenges associated with the production and application of bispecific antibodies.

Bispecific Antibodies Market: Opportunities

Ongoing innovation in the field of BsAbs will generate massive growth opportunities during the projection period

The global bispecific antibodies market is expected to generate growth opportunities due to the ongoing innovation in the industry. BsAbs researchers and developers are increasingly focusing on improving the overall application of the treatment and its efficiency in treating serious conditions.

For instance, according to the latest findings, bispecific antibodies are highly effective in treating relapsed/refractory multiple myeloma. During the coming years, the advancements in the ways in which the agents are used could further impact the results in treating the condition with BsAbs.

In August 2023, the American Association of Cancer Research published a report indicating the results of a phase I/II clinical trial that was presented at the 2023 annual meeting of the agency. According to the reports, patients with relapsed multiple myeloma who received treatment with the two highest doses of REGN5459 had shown a 90.5% overall response rate. REGN5459 is a bispecific antibody targeting B-cell Maturation Antigen (BCMA) and Cluster of Differentiation 3 (CD3).

In August 2024, Merck & Company, a pharmaceutical giant, announced the acquisition of a drug produced by Curon Biopharmaceuticals. The drug company has registered significant potential advantages of the drug in treating autoimmune diseases and cancer.

Bispecific Antibodies Market: Challenges

Competition from alternate treatments and side effects of the treatment will challenge the market expansion rate

The global industry for bispecific antibodies is projected to be challenged by the competition the sector faces from alternate treatments such as cell therapies and monoclonal antibodies. Additionally, the side effects associated with the treatment using bispecific antibodies may further inhibit additional growth in the industry. The most commonly observed side effects include respiratory distress, fever, multi-organ failure, hypotension, and headache.

Bispecific Antibodies Market: Segmentation

The global bispecific antibodies market is segmented based on indication, distribution channel, and region.

Based on the indication, the global market divisions are inflammatory & autoimmune disorders, cancer, and others. In 2023, the highest demand was listed in the cancer segment. It dominated nearly 68.01% of the final market revenue. The growing number of cancer patients worldwide along with mounting pressure on healthcare companies to develop efficient treatment plans for cancer is fueling the segmental revenue. During the projection period, the inflammatory & autoimmune disorder segment is projected to grow at a CAGR of 36.81%.

Based on the distribution channels, the global market segments are retail pharmacies, hospital pharmacies, drug stores, and online channels. In 2023, majority control over the revenue was held by the hospital pharmacies segment. According to market research, over 43% of the total revenue was generated by hospital pharmacies. The considerably high demand for bispecific antibodies across major healthcare providers is fueling the segmental demand rate.

Bispecific Antibodies Market: Report Scope

Bispecific Antibodies Market: Regional Analysis

North America is expected to generate the highest growth rate during the projection period

The global bispecific antibodies market is expected to be led by North America during the forecast period. In 2023, the region held dominance over nearly 88.01% of the global revenue with the US acting as the major contributor. The growing investments in bispecific antibody research and development across the US are a leading reason for higher regional revenue.

In addition to this, the commercialization speed of bispecific antibodies across the US and Canadian healthcare has played a pivotal role in ensuring that North America remains ahead in the race. The presence of major healthcare and drug research companies and institutions such as Eli Lilly and Company, Pfizer, Biogen, Merck & Co, and others will ensure the region's dominance over the global market share in the coming years.

Europe is anticipated to emerge as a significant contributor driving the consumption and research on BsAbs. The growing prevalence of cancer across major European countries along with the increasing incorporation of novel medical techniques and treatments for managing autoimmune disorders will drive the regional growth rate. Europe is projected to secure a CAGR of more than 47% during the projection period. Increasing government regulations supporting medical research and development will be critical to Europe’s expansion in the coming years.

Bispecific Antibodies Market: Competitive Analysis

The global bispecific antibodies market is led by players like:

• Regeneron Pharmaceuticals
• Gilead Sciences
• Genmab
• Janssen Biotech (Johnson & Johnson)
• Bristol-Myers Squibb
• Affimed
• Amgen
• Novartis
• Eli Lilly
• Merus
• Roche
• Pfizer
• Xencor
• Sanofi
• AbbVie

The global bispecific antibodies market is segmented as follows:

By Indication

• Inflammatory & Autoimmune Disorder
• Cancer
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Drug Stores
• Online Channels

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa